Last reviewed · How we verify
Fluoxetine+Olanzapine — Competitive Intelligence Brief
marketed
SSRI + atypical antipsychotic combination
Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor
Psychiatry
Small molecule
Live · refreshed every 30 min
Target snapshot
Fluoxetine+Olanzapine (Fluoxetine+Olanzapine) — University Health Network, Toronto. Fluoxetine inhibits serotonin reuptake while olanzapine blocks dopamine and serotonin receptors, combining antidepressant and antipsychotic effects.
Comparator set (2 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Fluoxetine+Olanzapine TARGET | Fluoxetine+Olanzapine | University Health Network, Toronto | marketed | SSRI + atypical antipsychotic combination | Serotonin transporter (SERT), dopamine D2 receptor, serotonin 5-HT2A receptor | |
| Escitalopram+Aripiprazole | Escitalopram+Aripiprazole | Ministry of Health & Welfare, Korea | marketed | SSRI + atypical antipsychotic combination | Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT1A receptor | |
| Sertraline + Olanzapine | Sertraline + Olanzapine | Weill Medical College of Cornell University | marketed | SSRI + atypical antipsychotic combination | Serotonin transporter (SERT); dopamine D2 receptor; serotonin 5-HT2A receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (SSRI + atypical antipsychotic combination class)
- Ministry of Health & Welfare, Korea · 1 drug in this class
- University Health Network, Toronto · 1 drug in this class
- Weill Medical College of Cornell University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Fluoxetine+Olanzapine CI watch — RSS
- Fluoxetine+Olanzapine CI watch — Atom
- Fluoxetine+Olanzapine CI watch — JSON
- Fluoxetine+Olanzapine alone — RSS
- Whole SSRI + atypical antipsychotic combination class — RSS
Cite this brief
Drug Landscape (2026). Fluoxetine+Olanzapine — Competitive Intelligence Brief. https://druglandscape.com/ci/fluoxetine-olanzapine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab